Retatrutide and Warfarin: Interaction Evidence Record

At a glance

• Review question / Is there FDA-reviewed or study-specific interaction evidence for retatrutide and Warfarin?
• Best evidence / a named pharmacokinetic registry record
• Evidence snapshot / 2026-08-09
• Commercial status / no FDA-approved product or ordinary retail supply
• HealthRX role / independent educational review; no retatrutide product or treatment offer

Direct answer

The answer is limited. Warfarin is an anticoagulant included in a registered pharmacokinetic study. A completed phase 1 registry record specifically measured pharmacokinetic endpoints relevant to this question. That narrow experiment does not create an FDA-reviewed interaction table, an overall safety conclusion, or public-use instructions.

The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.

Evidence map for Warfarin interaction evidence

How HealthRX evaluated this question

Interaction evidence has levels. A named pharmacokinetic study can measure exposure under controlled conditions; a clinical outcomes study can examine events in a defined population; an FDA label can synthesize reviewed evidence into instructions. Background use, anecdotes, and mechanism-based reasoning sit below those sources and should not be presented as settled guidance.

For this page, HealthRX asked: (1) Is warfarin interaction evidence named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.

Evidence checks specific to this record

Regulatory checkpoint

Search for a controlling FDA action after reviewing trials and publications. For warfarin interaction evidence, a study completion date, peer-reviewed paper, company announcement, or expanded-access entry does not replace an approval letter and approved prescribing information.

Question-to-source fit

Use the source that can actually answer the question. FDA records control regulatory status, registries document study plans, protocols define methods, and publications report analyses. For warfarin interaction evidence, a lower-level source should not be used to make a higher-level claim.

External validity

Ask whether the study setting resembles the setting implied by the question. Intensive visits, exclusion criteria, investigational-product controls, and protocol support can limit how observations about warfarin interaction evidence transfer beyond the research environment.

Replication threshold

One record can establish that a question was studied. Confidence in warfarin interaction evidence grows when methods and findings are reproduced in an appropriate population, reported completely, and reconciled with the broader evidence base. Replication is different from repetition of the same dataset.

Terminology discipline

Keep 'investigational,' 'registered,' 'completed,' 'published,' 'expanded access,' and 'FDA-approved' distinct. For warfarin interaction evidence, these terms describe different stages or pathways and should never be collapsed into the idea that a commercial treatment is available.

What remains unresolved

Retatrutide has no FDA-approved prescribing information or FDA-reviewed interaction table. Mechanism-based guesses, class analogies, anecdotes, and use of Warfarin as background therapy cannot establish whether concurrent use is safe, unsafe, beneficial, or appropriate.

The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.

What evidence could change the answer

The strongest future evidence would be a registered study naming Warfarin, prespecifying pharmacokinetic or clinical endpoints, documenting exposure and timing, and publishing complete results.

Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.

Current federal and commercial status

Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.

Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.

Source selection and review method

HealthRX reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov pharmacokinetic record NCT05445232; Rosenstock et al., phase 2 type 2 diabetes trial report; Jastreboff et al., phase 2 obesity trial report; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.

Frequently asked questions

›Is there an FDA-reviewed interaction table for Warfarin?

No. Retatrutide has no FDA-approved prescribing information and therefore no FDA-reviewed public interaction table.

›Does no dedicated study mean there is no interaction?

No. Absence of a named study is an evidence gap, not proof that concurrent use is compatible or incompatible.

›What source would answer the question best?

A registered study that names the substance, prespecifies pharmacokinetic or clinical endpoints, and publishes complete results would be more informative. FDA-reviewed labeling would be needed for public-use instructions.

References

1. ClinicalTrials.gov. Retatrutide pharmacokinetic interaction-study record. 2026. https://clinicaltrials.gov/study/NCT05445232
2. Rosenstock J, Frias J, Jastreboff AM, et al. Phase 2 retatrutide type 2 diabetes trial report. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
3. Jastreboff AM, Kaplan LM, Frias JP, et al. Phase 2 retatrutide obesity trial report. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
4. U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7